Open Nav

DotBio Pte. Ltd.

  • Ignacio Asial, DotBio Pte. Ltd.

Present the company and current progress

  • Date:Wednesday, October 17
  • Time:2:15 PM - 2:30 PM
  • Room:Elizabethan B
  • Location:2nd Floor
  • Session Type:Company Presentation
  • Presentation Type:Privately Funded Company
  • Company Description/Mission Statement:DotBio is an early-stage Biopharma company specialized in next-generation antibody therapies, with a particular focus in immuno-oncology. DotBio has a proprietary humanized, stable Domain Therapeutic Antibody (“DotBody”) technology that will revolutionize multi-specific therapies, antibody-drug conjugates and CAR-T therapies. We currently possess proprietary state-of-the-art DotBody and Fab phage display libraries, as well as numerous pre-clinical assets in the immuno-oncology field.
  • Company
  • Company HQ City:Singapore
  • Company HQ Country:Singapore
  • Main Therapeutic Focus:Oncology
  • Lead Product in Development :N/A.
  • Development Phase of Primary Product:Pre-Clinical
  • Total Amount Raised to Date, In All Rounds:US$ 2.3 million
Ignacio Asial
DotBio Pte. Ltd.